378 related articles for article (PubMed ID: 30411263)
1. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
4. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
[No Abstract] [Full Text] [Related]
6. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
7. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
8. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
9. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
10. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
11. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
13. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
14. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
15. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
Wood BL
Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
[TBL] [Abstract][Full Text] [Related]
16. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
18. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
20. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]